{
    "id": "5c6e4c9d-b85e-493f-9420-ab2fd0ff3723",
    "indications": {
        "text": "cholbam bile acid indicated : \u2022 treatment bile acid synthesis disorders due single enzyme defects ( seds ) . ( 1.1 ) \u2022 adjunctive treatment peroxisomal disorders ( pds ) including zellweger spectrum disorders patients exhibit manifestations liver disease , steatorrhea complications decreased fat-soluble vitamin absorption . ( 1.2 ) limitations : safety effectiveness cholbam extrahepatic manifestations bile acid synthesis disorders due seds pds including zellweger spectrum disorders established . ( 1.3 ) .",
        "doid_entities": [
            {
                "text": "liver disease (DOID:409)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_409"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 recommended 10 15 mg/kg daily two divided doses , pediatric patients adults . prescribing information weight-based dosing tables . ( 2.1 ) \u2022 recommended patients concomitant familial hypertriglyceridemia 11 17 mg/kg daily two divided doses adjusted based response . ( 2.1 ) \u2022 monitor ast , alt , ggt , alkaline phosphatase , bilirubin inr every month first 3 months , every 3 months next 9 months , every 6 months next three years annually thereafter . administer lowest dose effectively maintains liver function . ( 2.2 ) \u2022 discontinue cholbam liver function improve within 3 months starting treatment , complete biliary obstruction develops , persistent laboratory indicators worsening liver function cholestasis ; continue monitor liver function consider restarting lower dose parameters return baseline . ( 2.2 , 5.1 ) instructions : \u2022 take food . ( 2.3 ) \u2022 crush chew capsules . patients unable swallow capsules , capsules opened contents mixed drink/food ( 2.3 )",
        "doid_entities": [
            {
                "text": "familial hypertriglyceridemia (DOID:1172)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1172"
            },
            {
                "text": "cholestasis (DOID:13580)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_13580"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "50 mg capsules cholbam capsules available two-piece gelatin capsules swedish orange cap imprinted \u201c 50mg \u201d swedish orange body imprinted \u201c ask001 \u201d . capsules contain white off-white powder supplied bottles : \u202290 capsules ( ndc 79378-001-02 ) 250 mg capsules cholbam capsules available two-piece gelatin capsules white cap imprinted \u201c 250mg \u201d white body imprinted \u201c ask002 \u201d . capsules contain white off-white powder supplied bottles : \u202290 capsules ( ndc 79378-002-02 ) storage handling store 20\u00b0c\u201325\u25cbc ( 68\u00b0f\u201377\u25cbf ) , excursions permitted 15\u00b0c\u201330\u25cbc ( 59\u00b0f\u201386\u25cbf ) [ usp controlled room temperature ] .",
    "adverseReactions": "none .",
    "ingredients": [
        {
            "name": "CHOLIC ACID",
            "code": "G1JO7801AE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16359"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "CROSPOVIDONE, UNSPECIFIED",
            "code": "2S7830E561"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5291"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        }
    ],
    "organization": "Mirum Pharmaceuticals Inc.",
    "name": "CHOLBAM",
    "effectiveTime": "20250509",
    "indications_original": "CHOLBAM is a bile acid indicated for: \u2022 Treatment of bile acid synthesis disorders due to single enzyme defects (SEDs). ( 1.1 ) \u2022 Adjunctive treatment of peroxisomal disorders (PDs) including Zellweger spectrum disorders in patients who exhibit manifestations of liver disease, steatorrhea or complications from decreased fat-soluble vitamin absorption. ( 1.2 ) Limitations of use: The safety and effectiveness of CHOLBAM on extrahepatic manifestations of bile acid synthesis disorders due to SEDs or PDs including Zellweger spectrum disorders have not been established. ( 1.3 ).",
    "contraindications_original": "\u2022 The recommended dosage is 10 to 15 mg/kg once daily or in two divided doses, in pediatric patients and adults. See prescribing information for weight-based dosing tables. ( 2.1 ) \u2022 The recommended dosage in patients with concomitant familial hypertriglyceridemia is 11 to 17 mg/kg once daily or in two divided doses and is adjusted based on clinical response. ( 2.1 ) \u2022 Monitor AST, ALT, GGT, alkaline phosphatase, bilirubin and INR every month for the first 3 months, every 3 months for the next 9 months, every 6 months during the next three years and annually thereafter. Administer the lowest dose that effectively maintains liver function. ( 2.2 ) \u2022 Discontinue CHOLBAM if liver function does not improve within 3\u00a0months of starting treatment, if complete biliary obstruction develops, or if there are persistent clinical or laboratory indicators of worsening liver function or cholestasis; continue to monitor liver function and consider restarting at a lower dose when parameters return to baseline. ( 2.2 , 5.1 ) Administration Instructions: \u2022 Take with food. ( 2.3 ) \u2022 Do not crush or chew the capsules. For patients unable to swallow the capsules, the capsules can be opened and the contents mixed with drink/food ( 2.3 )",
    "warningsAndPrecautions_original": "50 mg Capsules\n                  \n                  CHOLBAM capsules are available as two-piece gelatin capsules with a Swedish orange cap imprinted with \u201c50mg\u201d and Swedish orange body imprinted with \u201cASK001\u201d. The capsules contain a white or off-white powder and are supplied in bottles of: \n                  \n                     \n                        \u202290 capsules (NDC 79378-001-02)\n                  \n                  \n                     250 mg Capsules\n                  \n                  CHOLBAM capsules are available as two-piece gelatin capsules with a white cap imprinted with \u201c250mg\u201d and white body imprinted with \u201cASK002\u201d. The capsules contain a white or off-white powder and are supplied in bottles of:\n                  \n                     \n                        \u202290 capsules (NDC 79378-002-02)\n                  \n                  \n                     Storage and Handling\n                  \n                  Store at 20\u00b0C\u201325\u25cbC (68\u00b0F\u201377\u25cbF), excursions permitted between 15\u00b0C\u201330\u25cbC (59\u00b0F\u201386\u25cbF) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "None.",
    "drug": [
        {
            "name": "CHOLBAM",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16359"
        }
    ]
}